Pharmaceutical Technology
MARCH 16, 2023
The partnership will use nanotechnology, which was proven in vivo, for providing antibodies inside tumour cells and provides a potential solution to address the medical challenge. These antibodies will be provided to pharma companies for conducting late-stage development and marketing.
pharmaphorum
JANUARY 29, 2021
Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities. Sangamo CEO Sandy Macrae told us how his company is being cautious about the hype and finding ways to be financially viable in an emerging space. Zinc fingers. billion in funding.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
AUGUST 17, 2020
To learn more about innovations in the field, Xtalks spoke to Anish Suri, PhD, president and chief scientific officer of Cue Biopharma about the company’s initiatives in the development of immune-based biological compounds for the treatment of cancers and autoimmune diseases. protein-based biologics) and vaccine treatments.
Drug Discovery World
SEPTEMBER 28, 2022
Its application in pharma, most commonly in drug discovery, has been steadily growing with global partnerships between tech vendors and pharma companies becoming more commonplace. According to Hampleton Patners’ latest Healthtech M&A market report2, digital health companies raised a total of $57.2
Drug Discovery World
APRIL 3, 2023
From humble beginnings in the founder’s basement, UK-based Aptamer Group is now supplying its Optimer binders to clients across big pharma. Addressing this need in the market has allowed us penetration to work with 75% of the top twenty pharma companies. DDW’s Diana Spencer caught up with co-founder and CEO Dr Arron Tolley.
Drug Discovery World
OCTOBER 4, 2022
New York-based Oligomerix is an emerging clinical-stage biotechnology company focused on developing disease-modifying therapeutics for neurodegenerative diseases characterised by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD) to Alzheimer’s disease (AD).
Drug Discovery World
NOVEMBER 15, 2022
Developed with the idea of engineering an enzyme called terminal deoxynucleotidyl transferase (TdT), a type of DNA polymerase, these enzymatic DNA synthesis methods are now the focus of dozens of companies. Anita Ramanathan outlines four synthetic biology approaches that are improving and accelerating drug discovery. .
Expert insights. Personalized for you.
262 
Let's personalize your content